Skip to content Skip to footer
Subscribe Now
2025 BioPharma Deals: The Survival Series | Nov 24-25 | Munich, Germany
EVENTS

2025 BioPharma Deals: The Survival Series | Nov 24-25 | Munich, Germany

BioPharma Deals: The Survival Series brings together leaders from biotech, pharma, investment, CRO/CDMO, legal, and advisory sectors for a high-impact event focused on pragmatic deal-making, new financing models, early IPOs, and unconventional partnerships. This is not a conference about the distant future. It's a working summit for what can be done now. It's about survival,…
August 18, 2025

Read more

SPOTLIGHT

CXO Talks: Colin Banas from DrFirst in an Illuminating Conversation with PharmaShots 

In the CXO Talks podcast, PharmaShots engaged in a riveting dialogue exchange with Colin Banas, Chief Medical Officer at DrFirst. Colin highlights the evolution of DrFirst from becoming a leader in the e-prescribing space to an end-to-end medication management company  Colin talks about its collaborators, Wise Hospice Options, achieving a new milestone by reducing the…
May 12, 2025

Read more

NEWS

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots: In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to…
January 15, 2025

Read more

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)
INSIGHTS+

J.P. Morgan Special: Dealmaker of the Year 2024 (Part 02)

Shots:   In this second installment of Dealmaker 2024, PharmaShots presents an insightful guide to the top M&A deals ranked by deal value This report highlights Novo Nordisk’s remarkable achievements, including 24 collaborations spanning acquisitions, company formations, contract services, development and commercialization agreements, facility purchases, licensing options, and platform/product purchases. Collectively, these deals amount to a…
January 15, 2025

Read more